Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Guidelines

ESCMID COVID-19 guidelines: diagnostic testing for SARS-CoV-2

Paraskevi C. Fragkou1,2, Giulia De Angelis3,4, Giulia Menchinelli3,4, Fusun Can5,6,7, Federico Garcia7,8,9, Florence Morfin-Sherpa9,10, Dimitra Dimopoulou2,10, Elisabeth Mack11, Adolfo de Salazar7,8, Adriano Grossi12, Theodore Lytras13, Chrysanthi Skevaki2,14,*

1) First Department of Critical Care Medicine & Pulmonary Services, Evangelismos General Hospital, National and Kapodistrian University of Athens, Athens, Greece
2) European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Respiratory Viruses, Basel, Switzerland
3) Dipartimento di Scienze Biotecnologiche di Base, Cliniche Intensiveologiche e Perioperatorie, Università Cattolica del Sacro Cuore, Rome, Italy
4) Dipartimento di Scienze di Laboratorio e Infettivologiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
5) Department of Medical Microbiology, Koc University School of Medicine, Istanbul, Turkey
6) Koc University IsBank Research Center for Infectious Diseases (KUISCID), Istanbul, Turkey
7) Servicio de Microbiología Clínica, Hospital Universitario Clínico San Cecilio, Instituto de Investigación Biosanitaria, Granada, Spain
8) CIBER de Enfermedades Infecciosas, CIBERINFEC, ISCIII, Madrid, Spain
9) Laboratory of Virology, Institut des Agents Infectieux, National Reference Centre for Respiratory Viruses, Hospices Civils de Lyon, Université Claude Bernard Lyon1, Lyon, France
10) Second Department of Paediatrics, P. and A. Kyriakou Children’s Hospital, National and Kapodistrian University of Athens, Athens, Greece
11) Department of Haematology, Oncology and Immunology, University Hospital Giessen and Marburg Campus Marburg and Faculty of Medicine, Philipps University Marburg, Marburg, Germany
12) Sezione di Igiene, Istituto di Sanità Pubblica, Università Cattolica del Sacro Cuore, Rome, Italy
13) School of Medicine, European University Cyprus, Nicosia, Cyprus
14) Institute of Laboratory Medicine, Universities of Giessen and Marburg Lung Center (UGMLC), Philipps University Marburg, German Center for Lung Research (DZL), Marburg, Germany

Article info

Article history:
Received 4 November 2021
Received in revised form 3 February 2022
Accepted 6 February 2022
Available online 23 February 2022
Editor: L. Leibovici

Keywords:
COVID-19
Diagnosis
Guidelines
SARS-CoV-2
Testing

Abstract

Scope: The objective of these guidelines is to identify the most appropriate diagnostic test and/or diagnostic approach for SARS-CoV-2. The recommendations are intended to provide guidance to clinicians, clinical microbiologists, other health care personnel, and decision makers.

Methods: An ESCMID COVID-19 guidelines task force was established by the ESCMID Executive Committee. A small group was established, half appointed by the chair and the remaining selected with an open call. Each panel met virtually once a week. For all decisions, a simple majority vote was used. A list of clinical questions using the PICO (population, intervention, comparison, outcome) format was developed at the beginning of the process. For each PICO, two panel members performed a literature search focusing on systematic reviews, with a third panelist involved in case of inconsistent results. Quality of evidence assessment was based on the GRADE-ADOLOPMENT (Grading of Recommendations Assessment, Development and Evaluation - adoption, adaptation, and de novo development of recommendations) approach.

Recommendations: A total of 43 PICO questions were selected that involve the following types of populations: (a) patients with signs and symptoms of COVID-19; (b) travellers, healthcare workers, and other individuals at risk for exposure to SARS-CoV-2; (c) asymptomatic individuals, and (d) close contacts of patients infected with SARS-CoV-2. The type of diagnostic test (commercial rapid nucleic acid amplification tests and rapid antigen detection), biomaterial, time since onset of symptoms/contact with an

* Corresponding author: Chrysanthi Skevaki, Institute of Laboratory Medicine and Pathobiochemistry, Molecular Diagnostics, Philipps University Marburg Baldingerstr, 35033 Marburg, Germany.
E-mail address: Chrysanthi.Skevaki@uk-gm.de (C. Skevaki).
† Giulia de Angelis and Giulia Menchinelli: equal contribution as second authors.
§ Fusun Can, Federico Garcia, Florence Morfin Sherpa: equal contribution as third authors.

https://doi.org/10.1016/j.cmi.2022.02.011
1198-743X/© 2022 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
Scope

The present guidelines have the objective of identifying the most appropriate diagnostic test and/or diagnostic/screening approach for (a) patients with signs and symptoms of COVID-19; (b) travellers from areas with low and high COVID-19 prevalence, health care workers, and other individuals at risk for exposure to SARS-CoV-2; (c) asymptomatic individuals (including the general population); (d) those with close contact with a person infected with SARS-CoV-2; and (e) symptomatic individuals after reinfec tion and/or vaccination.

However, evidence on reinfection and postvaccination testing approach was scarce when the literature search for the index guidelines was performed. Hence, associated patient/population, intervention, comparison and outcomes (PICO) could not be addressed. Additional considerations include the type of biomaterial, time since onset of symptoms/contact with infectious case, age, disease severity, and risk of developing severe disease. This document is intended to provide guidance to clinicians, clinical microbiologists, and other health care personnel, as well as decision makers.

Context

The ongoing COVID-19 pandemic has severely disrupted human life worldwide and represents an unprecedented challenge to public health [1]. As stated in the first paper of the newly developed European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for COVID-19 [2], ESCMID did not develop recommendations at the start of the pandemic. However, given the time that has passed and the rapid growth in evidence upon which to base recommendations, in January 2021 the ESCMID Executive Committee decided to launch a new initiative to develop ESCMID guidelines on several COVID-19–related issues. The present guideline provides recommendations for diagnostic testing for SARS-CoV-2, which is of particular relevance given the high incidence of both infections and deaths. This is further complicated by circulating mutations of SARS-CoV-2 and potential implications for diagnostic testing. Thus, a smart and effective approach to testing and screening is required to minimize the spread of the virus.

Consensus guideline development

The general principles and methodology adopted have been described in the first paper in the ESCMID guidelines for COVID-19–related clinical topics [2]. Herein, the panel members proposed a list of diagnostic PICO questions to the panel chair, who in turn selected the most clinically relevant questions and compiled a set of 55 priority PICO questions that reached consensus within the panel. Considering the available evidence, a total of 43 PICO questions were used for the development of the present guidelines. The PICO questions that were excluded are listed in Appendix S1, along with additional details on the methods used.

Quality of evidence assessment

The quality of the body of evidence was evaluated per the GRADE approach. Accordingly, five factors for rating down the quality of evidence (risk of bias, inconsistency of results, indirectness of evidence, imprecision, and publication bias) and three for rating it up (large magnitude of effect, direction of plausible confounding, dose-response gradient) were assessed. Adaptation of the quality assessment factors was applied by the panel for the diagnostic guidelines, as described in the following.

Risk of bias

The risk of bias of each study was assessed using the Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS–2) tool for diagnostic accuracy studies. The QUADAS–2 tool includes four key domains that discuss patient selection, index test, reference standard, and flow of patients through the study and timing of the index tests and reference standard. The QUADAS–2 assessment of studies included in the original systematic review was adopted, and two panel members independently assessed the QUADAS–2 for any new study retrieved during the evidence syntheses update, if performed (Methods S1). The risk of bias was judged to be very serious or serious if all or more/equal than a half of studies, respectively, had high or unclear concern regarding all or one to three QUADAS–2 domains. The risk of bias was judged not serious in any other case.

Indirectness

Indirectness was judged for all studies based on QUADAS–2 tool concerns for applicability for patient selection, index test, and reference standard. The QUADAS–2 applicability assessment of studies included in the original systematic review was adopted. Two panel members independently assessed the QUADAS–2 applicability for any new study retrieved during the systematic review update, if performed. Indirectness was judged to be very serious or serious if all or more/equal than half of studies, respectively, had high or unclear concern regarding all or one to two QUADAS–2 domains for applicability concerns. Indirectness was judged not serious in any other case. Furthermore, evidence was judged indirect if marked differences in the population with respect to the review question were suspected.

Inconsistency

Heterogeneity of results was assessed statistically with the $I^2$ test. We searched for a plausible source of heterogeneity by subgroup analyses according to the most plausible reason for heterogeneity (i.e. type of samples, type of test, and quality of studies). These subanalyses were performed only if subgroups included four or more studies. If a plausible explanation for heterogeneity was not identified, the quality of evidence was downgraded. Inconsistency was judged very serious if high and unexplained heterogeneity ($I^2 > 90\%$) was detected. Inconsistency was judged not serious if either low ($I^2 < 50\%$) or otherwise explained through subgroup analyses. Inconsistency was judged serious in any other case.
Table 1
PICO questions and recommendations in patients with signs and symptoms of COVID-19

| A | PICO question                                                                                           | Recommendation                                                                 | Strength of recommendation | Overall certainty of evidence | References |
|---|---------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------|------------------------------|-------------------------------|------------|
| 1 | In patients with signs and symptoms compatible with mild or moderate COVID-19, should commercial rapid NAAT be used, compared with standard NAAT (commercial and/or in house) for diagnosis of COVID-19? | In patients with signs and symptoms compatible with mild or moderate COVID-19, we suggest the use of rapid NAAT versus laboratory-based NAAT testing for the diagnosis of COVID-19. | Weak for                     | Very low            | [12–23]    |
| 2 | In patients with signs and symptoms compatible with severe or critical COVID-19, should commercial rapid NAAT testing be used, compared with standard NAAT testing (commercial and/or in house) for the diagnosis of COVID-19? | In patients with signs and symptoms compatible with severe or critical COVID-19, we suggest the use of rapid NAAT versus laboratory-based NAAT for the diagnosis of COVID-19. | Strong for                    | Very low            | [12–23]    |
| 3 | In patients with signs and symptoms compatible with COVID-19, should commercial rapid NAAT be used, compared with standard NAAT (commercial and/or in house) for diagnosis of COVID-19 in nasopharyngeal samples? | In patients with signs and symptoms compatible with COVID-19, we suggest the use of rapid NAAT in nasopharyngeal samples versus laboratory-based NAAT in nasopharyngeal samples for the diagnosis of COVID-19. | Weak for                     | Very low            | [13,15,16,18,20,22,23] |
| 4 | In patients with signs and symptoms compatible with COVID-19, should commercial rapid NAAT be used, compared with the standard NAAT (commercial and/or in house) for diagnosis of COVID-19 in samples other than nasopharyngeal swabs? | In patients with signs and symptoms compatible with COVID-19, we suggest the use of rapid NAAT in samples other than nasopharyngeal swabs versus laboratory-based NAAT in samples other than nasopharyngeal swabs for the diagnosis of COVID-19, when allowed by regulatory boards and manufacturer instructions. | Weak for                     | Very low            | [12,14,15,17,21,23] |
| 5 | In patients with signs and symptoms compatible with COVID-19 of ≤7 days' onset, should commercial rapid NAAT be used, compared with standard NAAT (commercial and/or in house) for diagnosis of COVID-19? | In patients with signs and symptoms compatible with COVID-19 of ≤7 days' onset, we suggest the use of rapid NAAT versus laboratory-based NAAT for the diagnosis of COVID-19. | Weak for                     | Very low            | [12–22]    |
| 6 | In patients with signs and symptoms compatible with COVID-19 of >7 days' onset, should commercial rapid NAAT be used, compared with standard NAAT (commercial and/or in house) for diagnosis of COVID-19? | In patients with signs and symptoms compatible with COVID-19 of >7 days' onset, we suggest the use of rapid NAAT versus laboratory-based NAAT for the diagnosis of COVID-19. | Weak for                     | Very low            | [12–23]    |
| 7 | In children ≤12 years old with signs and symptoms compatible with COVID-19, should commercial rapid NAAT be used, compared with standard NAAT (commercial and/or in house) for diagnosis of COVID-19? | In children ≤12 years old with signs and symptoms compatible with COVID-19, we suggest the use of rapid NAAT versus laboratory-based NAAT for diagnosis of COVID-19. | Weak for                     | Very low            | [12,15,17–20,22,23] |
| 8 | In patients >12 years old with signs and symptoms compatible with COVID-19, should commercial rapid NAAT be used, compared with standard NAAT (commercial and/or in house) for diagnosis of COVID-19? | In patients ≥12 years old with signs and symptoms compatible with COVID-19, we suggest the use of rapid NAAT versus laboratory-based NAAT for diagnosis of COVID-19. | Weak for                     | Very low            | [13,14,16,21,23] |
| 9 | In patients with signs and symptoms compatible with COVID-19 at risk for severe illness, should commercial rapid NAAT be used, compared with standard NAAT (commercial and/or in house) for diagnosis of COVID-19? | In patients with signs and symptoms compatible with COVID-19 at risk for severe disease, we suggest the use of rapid NAAT versus laboratory-based NAAT for diagnosis of COVID-19. | Weak for                     | Very low            | [12–23]    |
| 10 | Rapid antigen testing                                                                                                                                               | In patients with mild and moderate COVID-19, we suggest the use of laboratory-based NAAT versus rapid antigen detection testing for diagnosis of COVID-19. | Weak against                 | Very low            | [6,23–34]  |
| A | PICO question | Recommendation | Strength of recommendation[\textsuperscript{a}] | Overall certainty of evidence[\textsuperscript{b}] | References |
|---|---|---|---|---|---|
| 11 | In patients with signs and symptoms compatible with severe or critical COVID-19, should rapid antigen detection testing be used, compared with standard NAAT (commercial and/or in house) for diagnosis of COVID-19? | In patients with severe or critical COVID-19, we recommend the use of laboratory-based NAAT versus rapid antigen detection testing for diagnosis of COVID-19. | Strong against | Very low | [6,7,23,30,35–55, 56–88] |
| 12 | In patients with signs and symptoms compatible with COVID-19, should rapid antigen detection testing be used, compared with the standard NAAT (commercial and/or in house) for diagnosis of COVID-19 in nasopharyngeal samples? | In patients with signs and symptoms compatible with COVID-19, we suggest the use of laboratory-based NAAT in nasopharyngeal samples versus rapid antigen detection testing in nasopharyngeal samples for diagnosis of COVID-19. | Weak against | Very low | [6,7,23,24,26–29,32–36,38,39,41–43,45–52,55–64,69,72,73,75–77,80,81,85,86,89] |
| 13 | In patients with signs and symptoms compatible with COVID-19, should rapid antigen detection testing be used, compared with standard NAAT (commercial and/or in house) for diagnosis of COVID-19 in saliva samples? | In patients with signs and symptoms compatible with COVID-19, we suggest the use of laboratory-based NAAT in saliva samples versus rapid antigen detection testing in saliva samples for diagnosis of COVID-19. | Weak against | Very low | [6,7,23,30,40] |
| 14 | In patients with signs and symptoms compatible with COVID-19, should rapid antigen detection testing be used, with standard NAAT (commercial and/or in house) for diagnosis of COVID-19 in samples other than nasopharyngeal sample and saliva? | In patients with signs and symptoms compatible with COVID-19, we suggest the use of laboratory-based NAAT in samples other than nasopharyngeal and saliva samples versus rapid antigen detection testing in samples other than nasopharyngeal and saliva samples for diagnosis of COVID-19. | Weak against | Very low | [6,23,25,31,40,44,49,54,65–68,71,74,78,79,84,88] |
| 15 | In patients with signs and symptoms compatible with COVID-19 of ≤7 days’ onset, should rapid antigen detection testing be used, compared with standard NAAT (commercial and/or in house) for diagnosis of COVID-19? | In patients with signs and symptoms compatible with COVID-19 of ≤7 days’ onset, we suggest the use of laboratory-based NAAT versus rapid antigen detection testing for diagnosis of COVID-19. | Weak against | Very low | [6,7,23,25,28,30,33,41,49,52,59,60,68,71–73,78,82,84–86,88] |
| 16 | In patients with signs and symptoms compatible with COVID-19 of >7 days’ onset, should rapid antigen detection testing be used, compared with standard NAAT (commercial and/or in house) for diagnosis of COVID-19? | In patients with signs and symptoms compatible with COVID-19 of >7 days’ onset, we suggest the use of laboratory-based NAAT versus rapid antigen detection testing for diagnosis of COVID-19. | Weak against | Very low | [6,7,23,25,28,30,49,59,60,71,73,78,84,85] |
| 17 | In children <12 years old with signs and symptoms compatible with COVID-19, should rapid antigen detection testing be used, compared with standard NAAT (commercial and/or in house) for diagnosis of COVID-19? | In children <12 years old with signs and symptoms compatible with COVID-19, we suggest the use of laboratory-based NAAT versus rapid antigen detection testing for diagnosis of COVID-19. | Weak against | Very low | [6,23,52,71,79,86] |
| 18 | In patients ≥12 years old with signs and symptoms compatible with COVID-19, should rapid antigen detection testing be used, compared with standard NAAT (commercial and/or in house) for diagnosis of COVID-19? | In patients ≥12 years old with signs and symptoms compatible with COVID-19, we suggest the use of laboratory-based NAAT versus rapid antigen detection testing for diagnosis of COVID-19. | Weak against | Very low | [6,23,26,29,30,32,36,45–47,54–56,68,71,76,84,88] |
| 19 | In patients with signs and symptoms compatible with COVID-19 at risk for severe illness, should rapid antigen detection testing be used, compared with standard NAAT (commercial and/or in house) for diagnosis of COVID-19? | In patients with signs and symptoms compatible with COVID-19 at risk for severe illness, we recommend the use of laboratory-based NAAT versus rapid antigen detection testing for diagnosis of COVID-19. | Strong against | Very low | [6,23,46,60] |
| 20 | Saliva sampling | In patients with signs and symptoms compatible with mild or moderate COVID-19, should saliva sampling be used, compared with | Weak against | Very low | [90–97] |

(continued on next page)
Imprecision

We downgraded the evidence for imprecision if the boundaries of the 95% CIs of all or ≥50% of studies included a threshold of sensitivity or specificity for which the panel agreed that the estimate was adequate to support the decision. The panel agreed to set the threshold of sensitivity or specificity for all diagnostic tests encompassed by the guidelines at 80% or 90%, respectively.

Publication bias

Linear regression of log ORs on the inverse root of an effective sample-sizes test was used to assess the presence of publication bias when three or more studies were available [3,4]. Publication bias was strongly suspected if the p-value of the test was <0.10. Publication bias was considered strongly suspected when less than three studies informed the outcome and could not be excluded.

Definitions of tests

Rapid nucleic acid amplification tests (NAATs) were tests considered to have the capacity to be performed at the point of care or in a near-patient setting. This is decentralized testing requiring minimal equipment, sample preparation, and biosafety considerations that can be performed near a patient and outside of central laboratory testing [5]. Rapid antigen tests were defined as all commercially available tests, including both point of care (as defined above) and in-laboratory testing [6]. However, only one study provided information about in-laboratory testing [7].

Questions addressed by the guideline

In developing the guidelines for diagnosis of SARS-CoV-2, focus was placed on testing with commercial NAATs and rapid antigen detection. The performance characteristics of these tests depends on the population examined, viral prevalence in the community, and biomaterial used. Furthermore, the resources required to apply any of these tests and approaches depends on the local infrastructure of the individual setting and health care system facilities, including trained personnel, properly equipped diagnostic laboratories, and the types of tests being covered or reimbursed by the local health care system. Regarding particular recommendations for or against a specific test, the main beneficial outcomes considered were (a) reduction of mortality and facilitation of early treatment (if deemed to play a critical role), (b) reduction of viral transmission, (c) minimizing unnecessary
treatment and/or isolation, (d) reduction of anxiety of patients/potentially exposed persons, and (e) burden to health care systems with consequences for health inequality.

**Recommendations**

The 43 PICO questions selected were divided according to the target population: (A) patients with signs and symptoms of COVID-19 (Table 1); (B) travellers from areas with low COVID-19 prevalence, health care workers, and asymptomatic individuals at risk for exposure (5 questions; Table 2); and (C) asymptomatic individuals and those with close contact with an infected person (Table 3).

PICO questions in group A were further divided according to the type of test: (A1) commercial rapid NAAT versus standard NAAT (nine questions); (A2) rapid antigen testing versus standard NAAT (ten questions); and (A3) saliva sampling versus nasopharyngeal swabs for NAAT (seven questions). PICO questions in group C were further divided into (C1) rapid antigen testing versus NAAT (six questions) and (C2) NAAT in saliva samples versus nasopharyngeal swabs (six questions). A full summary of the evidence for each PICO question is presented in Appendices S2 through 4.

**Group A: Patients with signs and symptoms of COVID-19**

**Rapid NAAT**

The quality of the available evidence for all PICOs prioritized for patients with signs and symptoms compatible with COVID-19 was very low (Table 1). Along these lines, the strength of recommendation was almost always weak, except for cases where disease severity and/or risk of developing severe disease was considered of utmost importance. Diagnosis of COVID-19 with rapid NAAT will reduce the required time from sample acquisition to results. Extrapolation from studies looking into rapid NAATs for the detection of other respiratory viruses suggests that early isolation is beneficial [8]. In general, rapid NAAT is suggested due to the high accuracy of the test, low risk of anticipated harm, and feasible implementation. However, the anticipated benefits are likely to depend on the different risk factors for hospitalization, mortality, and associated morbidity.

**Rapid antigen testing**

Diagnosis of COVID-19 with rapid antigen testing will reduce the required time from sample acquisition to results and will reduce potential health inequities because antigen tests are (usually) readily available, easy to perform, and feasible to implement in various settings. This, in turn, will reduce the potential consequences of a delayed COVID-19 diagnosis or even the ability to perform COVID-19 testing when access is limited due to restricted resources. However, current data suggest that antigen tests are not as accurate as the reference standard NAATs (Table 1).

**Saliva sampling**

Laboratory-based NAAT in nasopharyngeal samples is the reference standard test for the diagnosis of COVID-19. The accuracy of other than nasopharyngeal samples, such as saliva, is being investigated. Saliva sampling is easier to perform with essentially no adverse events. However, saliva processing may be challenging unless collected in appropriate media because it has also been associated with aerosol generation [9,10]. Especially in some subgroups of patients, such as children, saliva might be preferred over nasopharyngeal swabs (Table 1). Nevertheless, children may not

---

**Table 2**

PICO questions and recommendations in travellers, health care workers, and asymptomatic individuals at risk for exposure

| B | PICO question | Recommendation | Strength of recommendation | Overall certainty of evidence | References |
|---|---------------|----------------|---------------------------|-----------------------------|------------|
| 1 | In travellers from areas with low prevalence, should surveys for contact history with known or suspected exposures to infected people followed by NAAT be used compared with universal NAAT to diagnose COVID-19? | In returning travellers from areas with low prevalence of COVID-19, we suggest the use of universal NAAT versus survey for contact history with known or suspected exposures in addition to NAAT for diagnosis of COVID-19. | Weak against | Very low | [119–121] |
| 2 | In travellers from areas with high prevalence, should surveys for contact history with known or suspected exposures to infected people followed by NAAT be used compared with universal NAAT to diagnose COVID-19? | In returning travellers from areas with high prevalence of COVID-19, we suggest the use of universal NAAT versus survey for contact history with known or suspected exposures in addition to NAAT for diagnosis of COVID-19. | Weak against | Very low | [121,122] |
| 3 | In health care workers, should surveys for contact history with known or suspected exposures to infected people followed by NAAT be used compared with universal NAAT to diagnose COVID-19? | In health care workers, we recommend the use of universal NAAT versus survey for contact history with known or suspected exposures in addition to NAAT for diagnosis of COVID-19. | Strong against | Very low | [119,121] |
| 4 | In asymptomatic populations at risk for exposure, should surveys for contact history with known or suspected exposures within <7 days to infected people followed by NAAT be used compared with universal NAAT to diagnose COVID-19? | In asymptomatic populations at risk for exposure, we suggest the use of universal NAAT versus survey for contact history with known or suspected exposures within <7 days in addition to NAAT for diagnosis of COVID-19. | Weak against | Very low | [119–122] |
| 5 | In asymptomatic populations at risk for exposure, should surveys for contact history with known or suspected exposures >7 days to infected people followed by NAAT be used compared with universal NAAT to diagnose COVID-19? | In asymptomatic populations at risk for exposure, we suggest the use of universal NAAT versus survey for contact history with known or suspected exposures >7 days in addition to NAAT for diagnosis of COVID-19. | Weak against | Very low | [119–122] |

NAAT, rapid nucleic acid amplification test; PICO, patient/population, intervention.

*Strength of recommendation (strong against, weak against, in research only, weak for, strong for).*

*Overall certainty of the evidence (high, moderate, low, very low).*
Table 3: PICO questions and recommendations in asymptomatic individuals and those with close contact with an infected person

| C  | PICO question                                                                 | Recommendation                                                                 | Strength of recommendationa | Overall certainty of evidenceb | References                                                                 |
|----|------------------------------------------------------------------------------|-------------------------------------------------------------------------------|------------------------------|--------------------------------|---------------------------------------------------------------------------|
| 1  | **Rapid antigen testing**                                                      | In asymptomatic children <12 years old without risk factors for severe COVID-19, should rapid antigen tests be used compared with laboratory-based NAAT to diagnose COVID-19? | Weak against                 | Very low                      | [6,23,30,33,40,51,62,67,79,83]                                             |
| 2  | In asymptomatic patients ≥12 years old without risk factors for severe COVID-19, should rapid antigen tests be used compared with laboratory-based NAAT to diagnose COVID-19? | We recommend laboratory-based NAAT in saliva samples versus rapid antigen testing for diagnosis of COVID-19. | Weak against                 | Very low                      | [6,23,26,27,31,45,46,48,54]                                             |
| 3  | In asymptomatic people of any age with any risk factor(s) for severe COVID-19 (including age <3 months or ≥65 years) should rapid antigen tests be used compared with laboratory-based NAAT to diagnose COVID-19? | In asymptomatic people of any age with any risk factor(s) for severe COVID-19 (including age <3 months or ≥65 years), we suggest the use of laboratory-based NAAT versus rapid antigen testing for diagnosis of COVID-19. | Weak against                 | Very low                      | [6,23,26,27,30,31,40,45,46,48,51,54] – [57,60,62,67,74,75,77–98,82,83] |
| 4  | In asymptomatic people, should rapid antigen test be used compared with laboratory-based NAAT in nasopharyngeal samples to diagnose COVID-19? | We recommend laboratory-based NAAT in nasopharyngeal samples versus rapid antigen testing in nasopharyngeal samples for diagnosis of COVID-19. | Weak against                 | Very low                      | [6,23,26,27,33,45,46,48,51,54] – [57,60,62,67,74,75,77,82,89]              |
| 5  | In asymptomatic people, should rapid antigen test be used compared with laboratory-based NAAT in non-nasopharyngeal/non-saliva samples to diagnose COVID-19? | We recommend laboratory-based NAAT in non-nasopharyngeal/non-saliva samples versus rapid antigen testing in non-nasopharyngeal/non-saliva samples for diagnosis of COVID-19. | Weak against                 | Very low                      | [6,23,31,40,67,74,78,79,83]                                             |
| 6  | In asymptomatic people, should rapid antigen test be used in saliva samples compared with laboratory-based NAAT to diagnose COVID-19? | In asymptomatic people, we suggest the use of laboratory-based NAAT in saliva samples versus rapid antigen testing in saliva for diagnosis of COVID-19. | Weak against                 | Very low                      | [6,23,30,40]                                                             |
| 7  | In asymptomatic children <12 years old, should NAAT in saliva samples be used compared with nasopharyngeal samples to diagnose COVID-19? | In asymptomatic children <12 years old, we suggest the use of NAAT in saliva samples versus NAAT in nasopharyngeal swab samples for diagnosis of COVID-19. | Weak for                      | Very low                      | [108,115,123,124]                                                       |
| 8  | In asymptomatic patients ≥12 years old, should NAAT test in saliva samples be used compared with nasopharyngeal samples to diagnose COVID-19? | In asymptomatic patients ≥12 years old, we suggest the use of NAAT in saliva samples versus NAAT in nasopharyngeal swab samples for diagnosis of COVID-19. | Weak against                 | Very low                      | [96,97,105,115,125]                                                     |
| 9  | In close-contact asymptomatic children <12 years old, should NAAT in saliva samples be used compared with nasopharyngeal samples to diagnose COVID-19? | In close-contact asymptomatic children <12 years old, we suggest the use of NAAT in saliva samples versus NAAT in nasopharyngeal swab samples for diagnosis of COVID-19. | Weak for                      | Very low                      | [126]                                                                  |
| 10 | In close-contact asymptomatic patients ≥12 years old, should NAAT in saliva samples be used compared with nasopharyngeal samples to diagnose COVID-19? | In close-contact asymptomatic patients ≥12 years old, we suggest the use of NAAT in saliva samples versus NAAT in nasopharyngeal swab samples for diagnosis of COVID-19. | Weak against                 | Very low                      | [96,105,115,124,125]                                                    |
| 11 | In close-contact asymptomatic children <12 years old with <7 days since contact, should NAAT in saliva samples be used compared with nasopharyngeal samples to diagnose COVID-19? | In close-contact asymptomatic children <12 years old with <7 days since contact, we suggest the use of NAAT in saliva samples versus NAAT in nasopharyngeal swab samples for diagnosis of COVID-19. | Weak for                      | Very low                      | [108,115,123,124]                                                       |
| 12 | In close-contact asymptomatic patients ≥12 years old with <7 days since contact, should NAAT in saliva samples be used compared with nasopharyngeal samples to diagnose COVID-19? | In close-contact asymptomatic patients ≥12 years old with <7 days since contact, we suggest the use of NAAT in nasopharyngeal swab samples versus NAAT in saliva samples for diagnosis of COVID-19. | Weak against                 | Very low                      | [96,97,105,115]                                                         |

NAAT, rapid nucleic acid amplification test; PICO, patient/population, intervention.

a Strength of recommendation (strong against, weak against, in research only, weak for, strong for).

b Overall certainty of the evidence (high, moderate, low, very low).
always be able to produce saliva on demand, and nasopharyngeal samples are still preferred in such cases. Notwithstanding, the available data suggest that the accuracy of saliva NAAT is not as high as nasopharyngeal NAAT.

**Group B: Travellers from areas with low and high COVID-19 prevalence, health care workers, and asymptomatic individuals at risk for exposure**

The quality of the available evidence for all PICOs prioritized for individuals at high risk of exposure to COVID-19 was very low (Table 2). Therefore, the strength of recommendation for all PICOs in this section is weak. NAAT driven by questioning for contact history or high-risk exposure is very inaccurate, with very low sensitivity. Despite the very low quality of evidence, the panel recommended against the use of NAAT driven by questioning for contact history or exposure in returning travellers from areas of low and high prevalence of COVID-19, health care workers, and asymptomatic individuals at risk for exposure instead of universal NAAT.

**Group C: Asymptomatic individuals and close contact of an infected person**

As for all previous PICOs, the quality of available evidence for asymptomatic individuals and close contacts was very low; thus, all recommendations are weak.

**Rapid antigen testing**

In asymptomatic individuals and those with close contact with an infected person, the use of laboratory-based NAAT should be preferred over rapid antigen testing for a diagnosis of COVID-19 (Table 3). The panel based its recommendations regarding rapid antigen testing on evidence from studies examining mainly the accuracy of first- and second-generation antigen tests that are not as accurate as third-generation ones [11].

**NAAT in saliva samples**

In asymptomatic children <12 years old (with or without close contact), NAAT of saliva samples was recommended over NAAT on nasopharyngeal swab samples for diagnosis of COVID-19 considering the accuracy of the test, the large anticipated benefits and small harm, low amount of resources, small incremental cost relative to net benefits, acceptability, and feasibility of the test (Table 3). In patients ≥12 years old, NAAT on nasopharyngeal samples should be preferred, also considering that young children may not produce saliva on command.

**Future considerations**

It is worthwhile to note that several gaps remain regarding the evidence for diagnostic testing in several areas. These include infection after vaccination or previous infection (reinfection), performance of newer-generation antigen tests in different patient populations and samples, correlation of viral nucleic acid or antigen detection with contagiousness, accuracy of different diagnostic tests in different populations and non-nasopharyngeal samples, and accuracy of different diagnostic tests in asymptomatic individuals and the general population. Moreover, there is a paucity of data regarding costs and/or resource modelling studies, patient values, preferences and beliefs, definitions of feasibility of various tests, stakeholders’ opinion regarding acceptability, and assessment criteria on the potential implications of interventions on health inequities. The lack of objective criteria to judge the priority of clinically relevant questions should also be highlighted, and very few data are available regarding the clinical impact (treatment, isolation, hospitalization) of these tests.

Furthermore, several methodological challenges were encountered that could be mitigated. First, literature databases specific for COVID-19 are not user friendly and are difficult to navigate. Especially for diagnostic testing, there was a lack of exportable literature. The ongoing pandemic also posed considerable time constraints for the development of guidelines, given the large amount of new information, as well as the need for regular updates and revisions of recommendations, all within a context with limited resources for guideline development.

Among the limitations of the present guidelines is the very low quality of evidence and lack of dedicated resources to update specific evidence syntheses. Furthermore, poorly disclosed methodological details in relevant meta-analyses did not allow for reproducibility of literature searches. We also included reagents for SARS-CoV-2 testing independently of the biomaterial for which they were optimized. We may thus not exclude the possibility that any unfavourable performance of a group of tests (e.g. pooled sensitivity of antigen tests) is due to diluting the favourable performance of tests, which are indeed optimized for one or another biomaterial. We also did not distinguish between different saliva samples, which may perform differently; thus, we cannot draw more specific conclusions in this regard.

In addition, it should be mentioned that this is not a systematic review, but rather guideline recommendations based on the GRADE ADOLPMENT methodology, which, by definition, is based on updating (if applicable) existing moderate-to-high quality already published (or preprint) evidence syntheses. Lastly, consensus was reached by a simple majority vote and not through consensus software/application, such as the Delphi technique, as suggested by the ESCMID Guidelines Committee. However, its strengths include the multidisciplinary expertise of the writing group and the transparent, structured, thorough, and sound methodological approach adopted.

**Transparency declaration**

CS has received consultancy and research funding from Hycor Biomedical, BencardAllergie, and Thermo Fisher Scientific, as well as research funding from Mead Johnson Nutrition. All other authors declare no conflicts of interest.

CS is supported by the Universities Giessen and Marburg Lung Center, the German Center for Lung Research, University Hospital Giessen and Marburg research funding according to article 2, section 3 cooperation agreement, and the Deutsche Forschungsgemeinschaft-funded SFB 1021 (Project identification: 197785619), KFO 309 (P10), and SK 317/1-1 (Project identification: 428518790), as well as the Foundation for Pathobiochemistry and Molecular Diagnostics. FG is supported, in part, by the Fundación Progreso y Salud, Consejería de Salud, Junta de Andalucía, and Acciones de Intensificación del personal investigador. EM is supported by the Foundation of the Faculty of Medicine, Philips University Marburg, Stiftung P. E. Kempees and Deutsche José Carreras Leukämie-Stiftung. All other authors declare no sources of funding.

**Author contributions**

Giulia De Angelis and Giulia Menchinelli contributed equally to this work. Fusun Can, Federico Garcia, and Florence Morfin-Sherpa contributed equally to this work.

The ESCMID panel members are Chrysanthis Skevaki (clinical microbiology, virology, infection epidemiology, and laboratory medicine), Paraskevi C. Fragkou (internal medicine and infectious
diseases), Giulia De Angelis (clinical microbiology, infection epidemiology, and infectious diseases), Giulia Menchinelli (clinical microbiology), Florence Morfin (clinical virology), Federico Garcia (clinical microbiology and infectious diseases), and Fusun Can (clinical microbiology).

Conceptualization and coordination of the overall scope of the guidelines: CS, PCF. First manuscript draft (e.g. scope/context, methodology, discussion): CS, PCF. Initial screening for available evidence synthesis: PCF, DD, EM. Information extraction/summary of existing relevant literature on methodological aspects: PCF, GDA, GM. Literature search for update of existing evidence syntheses: PCF, GDA, GM, DD, EM, AG. Data extraction: PCF, GDA, GM, FC, FG, FMS, DD, ADs. Additional meta-analyses: GDA, GM. Creation of SOFs: GDA, GM. First draft of final recommendations (completed summary templates of panel consensus): PCF, DD, PICO formulation and final selection, recommendations, and finalization of associated recommendations summary templates: CS, PCF, GDA, GM, FMS, FG, FC. Methodological consultation: TL, LS.

The panel will meet once a month to assess the need for further updates.

Acknowledgements

The authors acknowledge ESCMID for supporting medical writing services and the ESCMID Study Group on Respiratory Viruses. Medical writing assistance by Patrick Moore and methodology direction and overview by Luigia Scudellari are acknowledged. The authors also acknowledge the technical assistance of Chiara Speziale (ESCMID).

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.cmi.2022.02.011.

References

[1] Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA 2020;323:1239–42.

[2] Bartolotti M, Azap O, Barac A, Bussini I, Ergonul O, Krause R, et al. ESCMID COVID-19 living guidelines: drug treatment and clinical management. Clin Microbiol Infect 2022;28:222–38.

[3] Macaskill P, Walter SD, Irwig L. A comparison of methods to detect publication bias in meta-analysis. Stat Med 2001;20:641–54.

[4] Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. Comparison of two methods to detect publication bias in meta-analysis. JAMA 2006;295:676–80.

[5] Dinnes J, Deeks JJ, Berhane S, Taylor M, Adriano A, Davenport C, et al. Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection. Cochrane Database Syst Rev 2020. 8CD013705.

[6] Brummer LE, Katzenschlager S, Gaeddert M, Erdmann C, Schmitz S, Bota M, et al. Evaluation of a newly developed antigen test (QuickNavi-COVID19 Ag) for the diagnosis of SARS-CoV-2 in a point-of-care assay for the detection of SARS-CoV-2. Emerg Infect Dis 2020;9:1356–9.

[7] Cradic K, Lockhart M, Ozbolt P, Fatica L, Daudon M, Cardona M, et al. Accuracy of novel antigen rapid diagnostics for SARS-CoV-2 from nasopharyngeal and oropharyngeal swabs from symptomatic patients. J Clin Microbiol 2020;58. e00938–20.

[8] Moore NM, Li H, Schejbal D, Lindsay J, Hayden MK. Comparison of two commercial molecular tests and a laboratory-developed modification of the CDC 2019-nCoV reverse transcriptase PCR assay for the detection of SARS-CoV-2. J Clin Microbiol 2020;58. e00798–80.

[9] Soetje EA, Mahainainathan I, McCormick-Baw C, Cavuoti D, Lee F, Thomas A, et al. Saliva for use with a point of care assay for rapid diagnosis of COVID-19. Clin Chim Acta 2020;510:683–6.

[10] Thwe PM, Rets P. How many are we missing with ID NOW COVID-19 assay using direct nasopharyngeal swabs? Findings from a mid-sized academic hospital clinical microbiology laboratory. Diagn Microbiol Infect Dis 2020;98:115121.

[11] Wong RC, Wong AH, Ho YL, Leung EC, Lai RW. Evaluation on testing of deep throat saliva and lower respiratory tract specimens with Xpert Xpress SARS-CoV-2 assay. J Clin Virol 2020;131:104659.

[12] Abdulrahman A, Mustafa F, AlAwadhi AI, AlAnsari Q, AlAlawi B, Al Qahtani M. Evaluation of a newly developed antigen test (QuickNavi-COVID19 Ag) for the diagnosis of SARS-CoV-2 in a point-of-care assay for the detection of SARS-CoV-2. Clin Microbiol Infect 2020;26:133104659.

[13] Gyawali M, Stivala S, Gupta A, Chaudhary A, Amritkar V, Singh P, et al. Performance of a newly developed antigen test (QuickNavi-COVID19 Ag) for the diagnosis of SARS-CoV-2 in a point-of-care assay for the detection of SARS-CoV-2. Clin Microbiol Infect 2020;26:133104659.

[14] Fujimura K, Tsuchida K, Tsuchiya G, Tominaga S, Nakamura M, Nishimura K, et al. Evaluation of a newly developed antigen test (QuickNavi-COVID19 Ag) for the diagnosis of SARS-CoV-2 in a point-of-care assay for the detection of SARS-CoV-2. Clin Microbiol Infect 2020;26:133104659.

[15] Takeuchi Y, Akashi Y, Kato D, Kuwahara M, Muramatsu S, Ueda A, et al. The performance evaluation of the SAMBA II SARS-CoV-2 test for point-of-care detection of SARS-CoV-2. J Clin Microbiol 2020;59. e01262–20.

[16] Chen JH, Yip CC, Poon RW, Chan KH, Cheng VC, Hung IF, et al. Evaluation of the use of posterior oropharyngeal saliva in a point-of-care assay for the detection of SARS-CoV-2. Emerg Infect Dis 2020;9:1356–9.

[17] Collier DA, Assennato SM, Waris B, Sirholt N, Sharrocks K, Ritchie A, et al. Point of care nucleic acid testing for SARS-CoV-2 in hospitalized patients: a clinical validation trial and implementation study. Cell Rep Med 2020;1:10062.

[18] Yamamoto K, Suzuki M, Yamada G, Sudo T, Nomoto H, Kinoshita N, et al. Utility of the antigen test for coronavirus disease 2019 factors influencing the prediction of the possibility of disease transmission. Int J Infect Dis 2021;10465–72.
[35] Foundation for Innovative New Diagnostics. Evaluation of Bionote, Inc. NowCheck COVID-19 Ig Test—External report. Geneva: Switzerland; 2021. Evaluation of Innovative New Diagnostics.

[36] Foundation for Innovative New Diagnostics. Evaluation of SD Biosensor, Inc. STANDARD Q COVID-19 Ag Test—External report. Geneva, Switzerland: Foundation for Innovative New Diagnostics; 2020.

[37] Foundation for Innovative New Diagnostics. Evaluation of Abbott Panbio COVID-19 Ag Rapid Test Device—External report. Geneva, Switzerland: Foundation for Innovative New Diagnostics; 2020.

[38] Foundation for Innovative New Diagnostics. Evaluation of RapiGEN INC. BIOCREDT COVID-19 Antigen Rapid Test—External report. Geneva, Switzerland: Foundation for Innovative New Diagnostics; 2020.

[39] Fournier S, Audureau E, Chevaliez S, Pawlotsky JM. Evaluation de la performance diagnostique des tests rapides d’orientation diagnostique anti-gène SARS-CoV-2 en France. Laboratoire de virologie, département de prévention, diagnostic et traitement des infections: service de santé publique, hôpitaux universitaires Henri-Mondor, AP-HP, institut Mondor de recherche biomédicale (Inserm U959; université Paris Est-Créteil; 2020.

[40] Aguilo V, Fernandez-Gonzalez M, Ortiz de la Tabla V, Gonzalez-Jimenez N, Garcia JA, Masia M, et al. Evaluation of the rapid antigen test Panbio COVID-19 in saliva and nasal swabs in a population-based point-of-care study. Infect 2021;82:186–230.

[41] Albert E, Torres I, Bueno F, Huntley D, Molla E, Fernandez-Fuentes MA, et al. A rapid, high-sensitivity SARS-CoV-2 nucleocapsid immunoassay to aid diagnosis for Innovative New Diagnostics; 2020.

[42] Amin A, Baro B, Ouchi D, Rodo P, Ubals M, Corbacho-Monne M, et al. Performance and operational feasibility of the panbio COVID-19 antigen rapid testing device. J Infect 2021;82:186–230.

[43] Antona N, Yagi Y, Sashidhar T, Miyazaki T, et al. Evaluation of clinical utility of novel coronavirus antibody detection reagent, Epluse® SARSCoV-2. J Infect Chemother 2021;27:319–22.

[44] Beck ET, Paar P, Fojut I, Serwe J, Jahneh RK. Comparison of the Quidel Sofia SARS FIA test to the Hologic Aptima SARS-CoV-2 TMA test for diagnosis of COVID-19 in symptomatic and asymptomatic patients in Cameroon: a clinical, prospective, diagnostic accuracy study. Lancet Infect Dis 2021;21:1089–96.

[45] Caruana G, Crozatto A, Kampouri E, Kritikos A, Opota O, Foerster M, et al. Interlaboratory comparison of the Abbott BinaxNOW SARS-CoV-2 rapid antigen test in the emergency and the outpatient setting at a Swiss university hospital: the increase study. Microorganisms 2021;9:798.

[46] Cerutti F, Burdino E, Mila MG, Allice T, Gregori G, Bruzzone B, et al. Urgent need for rapid tests for SAR-CoV-2 antigen detection: evaluation of the SD-Biosensor antigen test for SARS-CoV-2. J Clin Virol 2020;132:104654.

[47] Courtielomett L, Guiraud J, Guillaume C, Gache S, Rezepcki Ve, Seve A, et al. High performance of a novel antigen detection test on nasopharyngeal specimens for diagnosing SARS-CoV-2 infection. J Med Virol 2021;93:3152–7.

[48] Drain PK, Ampajwala M, Chappel C, Gvozden AB, Hoppers M, Wang M, et al. A rapid, high-sensitivity SARS-CoV-2 nucleocapsid immunoassay to aid diagnosis of acute COVID-19 at the point of care: a clinical performance study. Infect Dis Ther 2021;10:753–69.

[49] Delgado P, Hurcych J, Sepkowitz KA, Briski A, Kulich M, Zajac M, et al. The sensiti- vity of SARS-CoV-2 antigen tests in the view of large-scale medRxiv. 2020;2021.11.23.20273198.

[50] Fenollar F, Bouam A, Ballouche M, Fuster L, Prudent E, Colson P, et al. Evaluation of the Panbio COVID-19 rapid antigen detection test device for the screening of patients with COVID-19. J Clin Microbiol 2021;59: e2589–20.

[51] Gonzalez-Donapetry P, Garcia-Clemente P, Bloise I, Garcia-Sanchez C, Sanchez Castellano MA, Romero MP, et al. Think of the children: evaluation of the Panbio COVID-19 rapid antigen test in pediatric population. Pediatr Infect Dis J 2021;40:385–8.

[52] Herrera V, Husi V, Adewale A, Johnson L, Hendrix T, Kuhlman J, et al. Testing healthcare workers exposed to COVID19 using rapid antigen detection. medRxiv 2020. 2020.08.12.20172726.

[53] Jacobsen KB, Jensen JS, Todsen T, Lippert F, Martel CJM, Klokker M, et al. Detection of SARS-CoV-2 infection by rapid antigen test in comparison with RT-PCR in a public hospital setting. Front Med (Lausanne) 2020;7:200361.

[54] Korenkov M, Poopalasingam N, Madler M, Vanshylla K, Eggeling R, Wirtz M, et al. Assessment of SARS-CoV-2 infectivity by a rapid antigen detection test. medRxiv 2021;2021.03.30.21254624.

[55] Kruger L, Gaeddert M, Tobian F, Lainati F, Gottschalk C, Klein JAF, et al. The Abbott Panbio WHO emergency use listed, rapid, antigen-detecting point-of-care device for SARS-CoV-2 infection diagnosis: Evaluation of the accuracy and ease-of-use. PLoS One 2016;11:e0247918.

[56] Kruger L, Gaeddert M, Tobian F, Lainati F, Gottschalk C, Klein JAF, et al. Diagnostic performance of a SARS-CoV-2 rapid antigen test in a large, Norwegian cohort. J Clin Virol 2021;137:e104789.

[57] Lindner AK, Nikolai O, Rauch F, Winkler W, Hofmann J, Stein A, Jones TC, et al. Antigen tests, nasopharyngeal PCR and saliva PCR to detect SARS-CoV-2: a comparative prospective clinical trial. medRxiv 2020. 2020.11.23.2037057.

[58] McClung JL, Hulsey TD, Hucks J, Johnson L, Hendrix T, Kuhlman J, et al. The Abbott Panbio COVID-19 rapid antigen test in children: implications for screening in a school setting. PLoS One 2021;16:e0249170.

[59] Stokes W, Berenger BM, Portnoy D, Scott B, Szelizicki J, Singh T, et al. Clinical performance of the Abbott Panbio with nasopharyngeal, throat, and saliva swabs among asymptomatic individuals with COVID-19. Eur J Clin Microbiol Infect Dis 2021;40:1721–6.

[60] Thommes L, Burkert FR, Ott KL, Goldin D, Loacker L, Langer S, et al. Comparative evaluation of four SARS-CoV-2 antigen tests in hospitalized patients with COVID 19. Int J Infect Dis 2021;105:1044–8.
Dogan OA, Zaboli A, Pfeifer N, Ciccariello L, Sibillo S, Tezza G, et al. Clinical application of a rapid antigen test for the detection of SARS-CoV-2 infection in symptomatic and asymptomatic patients evaluated in the emergency department: a preliminary report. J Infect 2021;82:e14–6.

Van der Moeren N, Zwart VF, Lodder EB, Van den Bijaardt W, Van Esch HRM, JMJ Stohr, et al. Performance evaluation of a SARS-CoV-2 rapid antigen test: test performance in the community of The Netherlands. medRxiv 2020. 2020.10.19.2125020.

Veyrenche N, Bollorie K, Pisoni A, Bedin AS, Mondain AM, Ducco J, et al. Diagnosis value of SARS-CoV-2: antigen/antibody combined testing using rapid diagnostic tests at hospital admission. J Med Virol 2021;93:3669–76.

Villaverde S, Dominguez-Rodriguez S, Sabrido G, Perez-Jorge C, Plata M, Romero MP, et al. Diagnostic accuracy of the Panbio severe acute respiratory syndrome coronavirus 2 antigen rapid test compared with reverse-transcriptase polymerase chain reaction testing of nasopharyngeal samples in the pediatric population. J Pediatr 2021;232:287–9.e284.

Weitzen T, Legarraga P, Furetagoyena M, Pizarro G, Vollrath V, Araos R, et al. Comparative evaluation of four rapid SARS-CoV-2 antigen detection tests using universal transport medium. Travel Med Infect Dis 2021;21:101942.

Young S, Taylor SN, Cammarata CL, Varnado KG, Roger-Dalbert C, Montano A, et al. Clinical evaluation of BD Veritor SARS-CoV-2 point-of-care test performance compared to PCR-based testing and versus the Sofia 2 SARS anti-gen point-of-care test. J Clin Microbiol 2020;59:e02338–20.

T Torres I, Poupou S, Albert E, Colomina J, Navarro D. Evaluation of a rapid antigen test (Panbio COVID-19 AG rapid test device) for SARS-CoV-2 detection in asymptomatic close contacts of COVID-19 patients. Clin Microbiol Infect 2021;27:631–6.e634.

Bhattacharya D, Parai D, Rout UK, Dash P, Nanda RR, Dash GC, et al. Saliva for diagnosis of SARS-CoV-2: first report from India. J Med Virol 2020;92:2529–33.

Braz-Silva PH, Mamana AC, Romano CM, Felix AC, de Paula AV, Fereira NE, et al. Performance of at-home self-collected saliva and naso- oropharyngeal swabs in the surveillance of COVID-19. J Oral Microbiol 2020;13:1858002.

Gucci E, Korglou M, Yuruzen Y, Toptan H, Kose E, Guneyus E, et al. Comparison of saliva and oro-nasopharyngeal swab sample in the molecular diagnosis of COVID-19. Rev Assoc Med Bras (2002) 2020;56:1116–21.

Hansson KE, Barker AP, Hillyard DR, Gilmore N, Barrett JW, Orlandi RR, et al. Self-collected anterior nasal and saliva specimens versus health care worker-collected nasopharyngeal swabs for the molecular detection of SARS-CoV-2. J Clin Microbiol 2020;58.e10182–20.

Landry ML, Criscuolo J, Peaper DR. Challenges in use of saliva for detection of SARS-CoV-2 RNA in symptomatic outpatients. J Clin Virol 2020;130:104567.

Sakasaki D, Aisi NA, Nakamura A, Miyazaki N, Kawamoto Y, Ohno T, et al. Comparative evaluation of nasopharyngeal swab and saliva specimens for the molecular detection of SARS-CoV-2 RNA in Japanese patients with COVID-19. Infect Chemother 2021;27:126–9.

Senok A, Aliuwadi H, Atrah Y, Al Aidy O, Al Zahid J, Han A, et al. Saliva as an alternative specimen for molecular COVID-19 testing in community settings and population-based screening. Infect Drug Resist 2020;13:3933–9.

Teo AKJ, Choudhury Y, Tan IB, Chew CY, Chew SW, Wan Z, et al. Saliva is more sensitive than nasopharyngeal or nasal swabs for diagnosis of asymptomatic and mild COVID-19 infection. Sci Rep 2021;11:3134.

Sita A, Basso D, Cattelan AM, Fioretto P, Navaglia F, Barbaro F, et al. SARS-CoV-2 identification in saliva: one sample two tests approach for diagnosis. Clin Chim Acta 2020:510717–22.

Becker D, Sandoval E, Amin A, De Hof P, Diets A, Leonetti N, et al. Saliva is less sensitive than nasopharyngeal swabs for COVID-19 detection in the community setting. medRxiv 2020. 2020.11.09.20219626.

Byrne RL, Kay GA, Kontogianni K, Aljayoussi G, Brown L, Collins AM, et al. Saliva alternative to upper respiratory swabs for SARS-CoV-2 diagnosis. Emerg Infect Dis 2020;26:2770–7.

Dogan OA, Kose B, Agaoglu NB, Yildiz J, Alkurk G, Demirkol YK, et al. Does sampling saliva increase detection of SARS-CoV-2 by RT-PCR? Comparing saliva with oro-nasopharyngeal swabs. J Virol Methods 2021;290:114049.

Echavarria M, Reyes NS, Rodriguez PE, Ypas M, Gaffney D, Cazares Y, Jaworski K, Byrd A, et al. Saliva as an alternate specimen source for detection of SARS-CoV-2 in asymptomatic patients using Cepheid Xpert Xpress SARS-CoV-2. J Clin Microbiol 2020;58:e01109–20.

McCormick-Raw C, Morgan K, Goldfarb DM, Tilley P, Al-Rawahi GN, Srigley JA, Ford G, et al. Comparative evaluation of four rapid SARS-CoV-2 infections in symptomatic patients using Cepheid Xpert Xpress SARS-CoV-2. J Clin Microbiol 2020;58:e01109–20.

Migures M, Mengelle C, Didier A, Alvarez M, Delobel P, et al. Saliva sampling for diagnosing SARS-CoV-2 infections in symptomatic patients and asymptomatic carriers. J Clin Virol 2020;130:104580.

Procop GW, Shrestha NK, Vogel S, Van Sickel K, Harrington S, Rhoads DD, et al. A direct comparison of enhanced saliva to nasopharyngeal swabs for the detection of SARS-CoV-2 in asymptomatic patients. J Clin Microbiol 2020;58:e01946–20.

Tsayamoto Y, Terada J, Kimura M, Moriya A, Motohashi A, Izumi S, et al. Diagnostic accuracy of nasopharyngeal swab, nasal swab and saliva swab samples for the detection of SARS-CoV-2 using RT-PCR. Infect Dis (Lond) 2021;53:581–9.

Uekama Y, Nagata M, Aoki W, Fujimori Y, Nakagawa T, Yokota H, et al. Accuracy and stability of saliva as a sample for reverse transcription PCR detection of SARS-CoV-2. J Clin Pathol 2021;74:67–8.

Vaz SN, Santos DS, Netto WM, Wang BK, Brites C. Validation of the Genexpert Xpress SARS-CoV-2 PCR assay using saliva as biological specimen. Braz J Infect Dis 2021:25:101543.

Vilar IM, da Costa VD, Marques BCL, da Silva LL, Santos AC, Mendonca A, et al. Usability of saliva samples for detecting SARS-CoV-2 RNA among liver disease patients. J Infect 2021;82:64–5.

Yee R, Truong TT, Pananraj PS, Eubanks N, Gai E, Jumargan J, et al. Saliva is a promising alternative specimen for the detection of SARS-CoV-2 in children and adults. J Clin Microbiol 2021;59:e02686–20.

Yokota I, Hattori T, Shane PY, Konno S, Nagasaki A, Takeyoubu K, et al. Equivalent SARS-CoV-2 viral loads by PCR between nasopharyngeal swab and saliva in symptomatic patients. Sci Rep 2021;11:4500.

Altawalah H, Alkurshah F, Alikandar WA, Ezkiouri S, Saliva specimens for detection of severe acute respiratory syndrome coronavirus 2 in Kuwaiti: a cross-sectional study. J Clin Virol 2020;132:104652.

Moreno-Contereras J, Espinoza MA, Sandoval-Jaime C, Cantu-Cuevas MA, Baron-Oliveres H, Ortiz-Orozco OD, et al. Saliva sampling and its direct lysis, an excellent option to increase the number of SARS-CoV-2 diagnostic tests in settings with supply shortages. J Clin Microbiol 2020;58.e01659–20.

Barrett ES, Horton DB, Roy J, Gennaro ML, Brooks A, Tischler E. Validation of the Genexpert Xpress SARS-CoV-2 PCR assay using saliva as biological specimen. Emerg Infect Dis 2021;73:e559.

Viswanathan M, Kahwati L, Jahn B, Giger K, Dobrescu AI, Hill C, et al. Universal screening for SARS-CoV-2 infection: a rapid review. Cochrane Database Syst Rev 2020:9:CD013718.

Hoehl S, Rabenau H, Berger A, Kortenbusch M, Cinatl J, Bokova J, et al. Evidence of SARS-CoV-2 infection in returning travelers from Wuhan, China. N Engl J Med 2020;382:1278–80.

Hasanoglu I, Korukoglu G, Asilturk D, Cogyun G, Kalem AK, Altas AB, et al. Higher viral loads in asymptomatic COVID-19 patients might be the invisible part of the iceberg. Infectious Disease 2021;49:117–26.

Yokota I, Shane PY, Okino S, Konno S, Nagasaki A, Takeyoubu K, et al. Saliva sampling and its direct lysis, an excellent option to increase the number of SARS-CoV-2 diagnostic tests in settings with supply shortages. J Clin Microbiol 2020;58.e01659–20.